CD40-CD40L and Platelet Function
2003; Lippincott Williams & Wilkins; Volume: 92; Issue: 9 Linguagem: Inglês
10.1161/01.res.0000074030.98009.ff
ISSN1524-4571
Autores Tópico(s)Blood properties and coagulation
ResumoHomeCirculation ResearchVol. 92, No. 9CD40-CD40L and Platelet Function Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBCD40-CD40L and Platelet FunctionBeyond Hemostasis Jane E. Freedman Jane E. FreedmanJane E. Freedman From the Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Mass. Originally published16 May 2003https://doi.org/10.1161/01.RES.0000074030.98009.FFCirculation Research. 2003;92:944–946Traditionally, platelets have been thought of as anuclear, subcellular fragments derived from megakaryocytes circulating in blood as small discs and mitigating hemorrhage. This hemostatic process requires platelet activation, a complex chain of events involving rapid structural changes that activate adhesion receptors, remodel the cytoskeleton, and lead to the eventual synthesis and secretion of various platelet-derived factors. The result of this cascade is the formation of platelet-dependent thrombosis that primarily attenuates bleeding but, in pathophysiological settings, contributes to occlusive vascular events. These clinical realities have led to the bias that platelets are primarily involved in thrombosis and hemostasis. This bias has been reflected in the predominant use of platelet aggregometry as the standard method for quantifying platelet activation ex vivo. This technique, however, only identifies platelet-platelet binding (homotypic aggregates) and, in clinical settings, has promoted a relatively simplistic vision of platelet function. The focus on platelet-dependent thrombosis has made the platelet aggregate a common therapeutic target in syndromes involving vascular occlusion. However, merely preventing the process of platelet-platelet binding may not always translate into clinical efficacy as seen in the recent disappointing results associated with the use of the oral IIb/IIIa inhibitors.1Recently, studies have suggested that platelets also participate in inflammatory reactions. Platelets are known to produce inflammatory mediators including platelet-derived growth factor, platelet factor 4, and transforming growth factor-β. Platelets are also known to bind, via P-selectin (CD62P) expressed on the surface of activated platelets to the leukocyte receptor, P-selectin glycoprotein ligand-1 (PSGL-1). The relevance of this binding is supported by a study demonstrating that the infusion of recombinant soluble human form of P-selectin glycoprotein ligand-1 in an animal model of vascular injury reduced myocardial reperfusion injury and preserved vascular endothelial function.2 The clinical implications of heterotypic aggregates are shown by studies demonstrating that after acute myocardial infarction, circulating monocyte-platelet aggregates are both increased and are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin.3 Plaque rupture promotes activation of the inflammatory responses, and the consistent finding of heterotypic aggregates highlights the close interaction between inflammation and thrombosis in vascular disease.Contributing to our understanding of the role of platelets in inflammation are CD40-CD40 ligand (CD40L) interactions. CD40 is a membrane glycoprotein belonging to the tumor necrosis family receptor superfamily and its ligand CD40L (CD154) is a glycoprotein from the tumor necrosis factor family. CD40-CD40L interactions are central in immune responses and inflammation. Ligation of CD40 on various vascular cells contributes to the pathogenesis of atherosclerotic, thrombotic, and inflammatory processes.4,5 On endothelial cells or monocytes, the engagement of CD40 leads to the synthesis of adhesion molecules, chemokines, and tissue factor and causes the activation of matrix metalloproteinases. CD40L has also been detected in platelets4 where, after stimulation, it is translocated to the platelet surface (Figure). The surface-expressed CD40 ligand is then cleaved from the platelet over a period of minutes to hours subsequently generating a soluble fragment (soluble CD40 ligand or sCD40L).6 It is estimated that >95% of the circulating sCD40L is derived from platelets.6 Found to be increased on platelets in fresh thrombus,4 sCD40L has been shown to be elevated in cardiovascular disease7,8 and associated with increased cardiovascular risk in apparently healthy women.9Download figureDownload PowerPointAfter platelet stimulation, CD40L is translocated to the platelet surface. Surface-expressed CD40 ligand is then cleaved from the platelet over a period of minutes to hours, subsequently generating a soluble fragment, sCD40L. Soluble CD40L can then promote inflammatory or thrombotic response by causing further platelet activation or, in high-shear settings, may enhance the formation of homotypic aggregates.Although sCD40L has been characterized as a marker of thrombotic diseases, much less is known about its direct role in platelet function. It has been suggested that CD40L is an αIIbβ3 ligand, a platelet agonist, and contributes to stability of arterial thrombi.6 In this issue of Circulation Research, Inwald and colleagues10 add to the limited information concerning the effects of sCD40L on platelet function and demonstrate that CD40 ligation may be a mechanism for platelet activation. After incubation of platelets with the trimeric form of sCD40L (sCD40LT), they showed enhanced CD62P expression as well as dense and α-granule release. Interestingly, the presence of a glycoprotein IIb/IIIa blocking agent did not alter sCD40LT-induced CD62P expression. In addition, β-thromboglobulin and [14C]-5-HT were shown to be present after ligation reflecting α- and dense granule release, respectively. An intriguing part of this study is the confirmatory data using subjects with X-linked hyper-IgM syndrome and known absence of CD40L expression. The ability to utilize these subjects is particularly interesting in platelet-dependent studies as genetic manipulation in cell culture is not possible.At issue is the form and concentration of sCD40L used in the studies. In the experiments, the concentration of sCD40LT used was 1 μg/mL although platelet activation was present at concentrations as low as 100 ng/mL. Although these concentrations are similar to those reported in the literature for CD40L activation of other cell types, it is still greater than the levels reported in patients (50 ng/mL). Although this discrepancy may question the clinical relevance of the findings of Inwald et al,10 it is possible that local concentrations in active areas of thrombotic or inflammatory disease are higher. This would allow a dose-dependent mechanism for targeting the effects of sCD40L. Further kinetic studies and assessment of in vivo concentrations are needed to answer the question of relevance in relation to the levels used in these studies. In addition, the trimeric form of sCD40L was used in the studies and it has been shown that the specific activity of sCD40L may depend on its form as a trimer or monomer. Although the membrane-bound CD40L may be trimeric,11 there is debate concerning the soluble form.4,11 Further studies, specifically in platelets, would be required to clarify this question.In the studies by Inwald et al,10 platelet activation via sCD40LT occurred in the presence of a αIIbβ3 inhibitor. This appears to be in contrast to previous work that demonstrates that sCD40L is an αIIbβ3 ligand.6 However, a more intriguing interpretation is that this is not only a novel means of platelet activation but that the platelet may be activated in distinct ways in different settings. In the present study by Inwald et al, incubation with sCD40LT resulted in significantly less CD62P expression compared with platelet activation with thrombin receptor agonist peptide 1-6 (SFLLRN). In addition, the increase in Pac-1 is minimal with sCD40L compared with SFLLRN. Differences in dense granule release were also detected with thrombin receptor stimulation leading to >5 times [14C]-5-HT levels compared with sCD40LT incubation. Similar results were not shown for β-thromboglobulin and further analysis of α-granules as well as the effects of other agonists would be of interest. However, it may be possible that in areas of relevant concentrations, the presence of sCD40L leads to selective activation and granule release but excludes the formation of homotypic aggregates. This possibility is strengthened by the finding that sCD40LT enhanced platelet-neutrophil formation occurs in the setting of minimal αIIbβ3 activation and that platelets from subjects deficient in CD40L aggregated normally. However, in the setting of high shear, αIIbβ3 may be engaged leading to thrombus formation. Thus, these differences could allow for a partial separation of the thrombotic and inflammatory roles of platelets. The mechanism for the sCD40L-induced cascade of platelet activation is not known. In the present study, the experiments suggesting that there was no change in calcium flux after sCD40L stimulation are too limited to draw conclusions or to infer that protein kinase C signaling is responsible. However, the possibility that ligation of CD40, as well as binding to αIIbβ3, can lead to outside-in signaling in the absence of inside-out signaling is intriguing. However, not all means of inside-out stimulation in platelets are calcium-dependent. To conclude that CD40-CD40L interactions are resulting in outside-in signaling or G protein–independent activation requires further examination.Although many questions remain, these findings help to clarify if sCD40L is released to further drive platelet-dependent thrombus formation or inflammatory reactions in the vasculature. The partial and selective activation that appears after engagement of CD40 suggests that the platelet is involved in both functions and that it may have the capacity to be differentially regulated. Continuing to define the role of platelets in inflammation and the extent to which its thrombotic functions are complementary will be challenging. The anuclear platelet is being rediscovered as an intriguing link between thrombosis and inflammation, and future research should provide great insight into platelet-dependent mechanisms leading to the regulation of vascular disease.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.This work was supported in part by NIH grants NIH RO1AG08226 (J.F.), NIH RO1HL62267 (J.F.), and an Established Investigator Award from the American Heart Association.FootnotesCorrespondence to Jane E. Freedman, MD, Boston University School of Medicine, 715 Albany St, W507, Boston, MA 02118. E-mail [email protected] References 1 Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001; 103: 201–206.CrossrefMedlineGoogle Scholar2 Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res. 1999; 41: 65–76.CrossrefMedlineGoogle Scholar3 Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001; 104: 1533–1537.CrossrefMedlineGoogle Scholar4 Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391: 591–594.CrossrefMedlineGoogle Scholar5 Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394: 200–203.CrossrefMedlineGoogle Scholar6 Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a β3 integrin– dependent mechanism. Nat Med. 2002; 8: 247–252.CrossrefMedlineGoogle Scholar7 Freedman JE. CD40 ligand–assessing risk instead of damage? N Engl J Med. 2003; 348: 1163–1165.CrossrefMedlineGoogle Scholar8 Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003; 348: 1104–1111.CrossrefMedlineGoogle Scholar9 Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD 40L and cardiovascular risk in women. Circulation. 2001; 104: 2266–2268.CrossrefMedlineGoogle Scholar10 Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003; 92: 1041–1048.LinkGoogle Scholar11 Peitsch MC, Jongeneel CV. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol. 1993; 5: 233–238.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Vulliamy P, Kornblith L, Kutcher M, Cohen M, Brohi K and Neal M (2020) Alterations in platelet behavior after major trauma: adaptive or maladaptive?, Platelets, 10.1080/09537104.2020.1718633, 32:3, (295-304), Online publication date: 3-Apr-2021. Bonaroti J, Zettel K, Billiar T and Neal M (2021) Disorder of Systemic Inflammation in Sepsis and Trauma: A Systems Perspective Complex Systems and Computational Biology Approaches to Acute Inflammation, 10.1007/978-3-030-56510-7_6, (99-129), . Morsilli O, Guerriero R, Lulli V, Maffei L, Pasquini L, Pulcinelli F, Sorrentino F and Gabbianelli M (2020) Platelet and megakaryocyte CD40L expression in β-Thalassemic patients, Thrombosis Research, 10.1016/j.thromres.2020.02.026, 189, (108-111), Online publication date: 1-May-2020. Schroder P, Fitch Z, Schmitz R, Choi A, Kwun J and Knechtle S (2019) The past, present, and future of costimulation blockade in organ transplantation, Current Opinion in Organ Transplantation, 10.1097/MOT.0000000000000656, 24:4, (391-401), Online publication date: 1-Aug-2019. Cuneo K, Devasia T, Sun Y, Schipper M, Karnak D, Davis M, Owen D, Feng M, El Naqa I, Bazzi L, Ten Haken R and Lawrence T (2019) Serum Levels of Hepatocyte Growth Factor and CD40 Ligand Predict Radiation-Induced Liver Injury, Translational Oncology, 10.1016/j.tranon.2019.04.003, 12:7, (889-894), Online publication date: 1-Jul-2019. Ben-Shaul S, Landau S, Merdler U and Levenberg S (2019) Mature vessel networks in engineered tissue promote graft–host anastomosis and prevent graft thrombosis, Proceedings of the National Academy of Sciences, 10.1073/pnas.1814238116, 116:8, (2955-2960), Online publication date: 19-Feb-2019. Karnell J, Rieder S, Ettinger R and Kolbeck R (2019) Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond, Advanced Drug Delivery Reviews, 10.1016/j.addr.2018.12.005, 141, (92-103), Online publication date: 1-Feb-2019. Senchenkova1 E, Russell J, Vital S, Yildirim1 A, Orr A, Granger D and Gavins1 F (2018) A critical role for both CD40 and VLA5 in angiotensin Il–mediated thrombosis and inflammation, The FASEB Journal, 10.1096/fj.201701068R, 32:6, (3448-3456), Online publication date: 1-Jun-2018. Oliveira R, Cordeiro M, Moura P, Baptista Filho P, Braga-Neto U, Marques E and Gil L (2017) Serum cytokine/chemokine profiles in patients with dengue fever (DF) and dengue hemorrhagic fever (FHD) by using protein array, Journal of Clinical Virology, 10.1016/j.jcv.2017.02.007, 89, (39-45), Online publication date: 1-Apr-2017. Momi S, Pitchford S, Gresele P and Page C (2017) Platelets and Airway Diseases Platelets in Thrombotic and Non-Thrombotic Disorders, 10.1007/978-3-319-47462-5_77, (1149-1168), . Myung W, Lim S, Woo H, Park J, Shim S, Lee S and Kim D (2016) Serum Cytokine Levels in Major Depressive Disorder and Its Role in Antidepressant Response, Psychiatry Investigation, 10.4306/pi.2016.13.6.644, 13:6, (644), . Alhawiti N, Burbury K, Kwa F, O'Malley C, Shuttleworth P, Alzard M, Hamadi A, Grigg A and Jackson D (2016) The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state, Thrombosis Research, 10.1016/j.thromres.2016.07.019, 145, (54-64), Online publication date: 1-Sep-2016. Lin X, Ten X, Tang X and Chen J (2015) Serum soluble CD40 ligand levels after acute intracerebral hemorrhage, Acta Neurologica Scandinavica, 10.1111/ane.12445, 133:3, (192-201), Online publication date: 1-Mar-2016. Gateva A, Assyov Y, Tsakova A and Kamenov Z (2016) Soluble CD40L is associated with insulin resistance, but not with glucose tolerance in obese nondiabetic patients, Archives of Physiology and Biochemistry, 10.3109/13813455.2016.1160934, 122:3, (161-165), Online publication date: 26-May-2016. Zhao P, Fang W, Chai L, Ruan J, Zheng Y, Jiang W, Lin S, Zhou S and Zhang Z (2015) The prognostic value of plasma soluble CD40 ligand levels in patients with nasopharyngeal carcinoma, Clinica Chimica Acta, 10.1016/j.cca.2015.05.015, 447, (66-70), Online publication date: 1-Jul-2015. Chaturvedi R, Gupta M, Jain A, Das T and Prashar S (2014) Soluble CD40 ligand: a novel biomarker in the pathogenesis of periodontal disease, Clinical Oral Investigations, 10.1007/s00784-014-1216-3, 19:1, (45-52), Online publication date: 1-Jan-2015. Pastori D, Esposito A, Carnevale R, Bartimoccia S, Novo M, Fantauzzi A, Di Campli F, Pignatelli P, Violi F and Mezzaroma I (2015) HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity, Journal of Infection, 10.1016/j.jinf.2015.01.005, 70:6, (651-658), Online publication date: 1-Jun-2015. Valdes V, Nardi M, Elbaum L and Berger J (2015) Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand, Journal of Thrombosis and Thrombolysis, 10.1007/s11239-015-1179-5, 40:1, (83-87), Online publication date: 1-Jul-2015. Chung H and Lim J (2014) Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma, Journal of Translational Medicine, 10.1186/1479-5876-12-102, 12:1, (102), . Ma A, Dun H, Song L, Hu Y, Zeng L, Bai J, Zhang G, Kinugasa F, Miyao Y, Sakuma S, Okimura K, Kasai N, Daloze P and Chen H (2014) Pharmacokinetics and Pharmacodynamics of ASKP1240, a Fully Human Anti-CD40 Antibody, in Normal and Renal Transplanted Cynomolgus Monkeys, Transplantation, 10.1097/01.TP.0000440951.29757.bd, 97:4, (397-404), Online publication date: 27-Feb-2014. Spiliopoulos S, Kassimis G, Hatzidakis A and Krokidis M (2013) High On-Treatment Platelet Reactivity in Peripheral Endovascular Procedures, CardioVascular and Interventional Radiology, 10.1007/s00270-013-0707-y, 37:3, (559-571), Online publication date: 1-Jun-2014. Brunekreeft K, Strohm C, Gooden M, Rybczynska A, Nijman H, Grigoleit G, Helfrich W, Bremer E, Siegmund D, Wajant H and de Bruyn M (2014) Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death, Molecular Cancer, 10.1186/1476-4598-13-85, 13:1, Online publication date: 1-Dec-2014. Ozkan G, Ulusoy S, Mentese A, Karahan S and Cansiz M (2013) New Marker of Platelet Activation, SCUBE1, Is Elevated in Hypertensive Patients, American Journal of Hypertension, 10.1093/ajh/hpt007, 26:6, (748-753), Online publication date: 1-Jun-2013. Jasinska T, Grzanka A, Machura E and Kasperska-Zajac A (2013) Is Delayed Pressure Urticaria Associated with Increased Systemic Release of sCD40L?, BioMed Research International, 10.1155/2013/823798, 2013, (1-4), . Azzam H, Abousamra N, Goda H, El-Shouky R and El-Gilany A (2013) The expression and concentration of CD40 ligand in normal pregnancy, preeclampsia, and hemolytic anemia, elevated liver enzymes and low platelet count (HELLP) syndrome, Blood Coagulation & Fibrinolysis, 10.1097/MBC.0b013e32835a8aca, 24:1, (71-75), Online publication date: 1-Jan-2013. Juhász K, Buzás K and Duda E (2014) Importance of reverse signaling of the TNF superfamily in immune regulation, Expert Review of Clinical Immunology, 10.1586/eci.13.14, 9:4, (335-348), Online publication date: 1-Apr-2013. Bremer E (2013) Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy, ISRN Oncology, 10.1155/2013/371854, 2013, (1-25), Online publication date: 11-Jun-2013. Azzam H, Abousamra N, Wafa A, Hafez M and El-Gilany A (2012) Upregulation of CD40/CD40L system in rheumatic mitral stenosis with or without atrial fibrillation, Platelets, 10.3109/09537104.2012.721906, 24:7, (516-520), Online publication date: 1-Nov-2013. Patko Z, Csaszar A, Acsady G, Peter K and Schwarz M (2012) Roles of Mac-1 and glycoprotein IIb/IIIa integrins in leukocyte–platelet aggregate formation: Stabilization by Mac-1 and inhibition by GpIIb/IIIa blockers, Platelets, 10.3109/09537104.2011.625098, 23:5, (368-375), Online publication date: 1-Aug-2012. Esposito P, Rampino T, Gregorini M, Gabanti E, Bianzina S and Dal Canton A (2012) Mechanisms underlying sCD40 production in hemodialysis patients, Cellular Immunology, 10.1016/j.cellimm.2012.06.007, 278:1-2, (10-15), Online publication date: 1-Jul-2012. Oberheiden T, Nguyen X, Fatar M, Elmas E, Blahak C, Morper N, Dempfle C, Hennerici M, Borggrefe M and Kälsch T (2011) Platelet and Monocyte Activation in Acute Ischemic Stroke—Is There a Correlation With Stroke Etiology?, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029611412359, 18:1, (87-91), Online publication date: 1-Jan-2012. Rückerl R, Schneider A, Breitner S, Cyrys J and Peters A (2011) Health effects of particulate air pollution: A review of epidemiological evidence, Inhalation Toxicology, 10.3109/08958378.2011.593587, 23:10, (555-592), Online publication date: 1-Aug-2011. Wu B, Zhi M, Liu H, Huang J, Zhou Y and Zhang T (2011) Inhibitory effects of lipoteichoic acid from Staphylococcus aureus on platelet function and platelet–monocyte aggregation, Inflammation Research, 10.1007/s00011-011-0333-6, 60:8, (775-782), Online publication date: 1-Aug-2011. Haller S, Adlakha S, Reed G, Brewster P, Kennedy D, Burket M, Colyer W, Yu H, Zhang D, Shapiro J and Cooper C (2011) Platelet Activation in Patients with Atherosclerotic Renal Artery Stenosis Undergoing Stent Revascularization, Clinical Journal of the American Society of Nephrology, 10.2215/CJN.03140411, 6:9, (2185-2191), Online publication date: 1-Sep-2011. Pignatelli P, Tanzilli G, Carnevale R, Di Santo S, Loffredo L, Celestini A, Proietti M, Tovaglia P, Mangieri E, Basili S and Violi F (2010) Ascorbic Acid Infusion Blunts CD40L Upregulation in Patients Undergoing Coronary Stent, Cardiovascular Therapeutics, 10.1111/j.1755-5922.2010.00168.x, 29:6, (385-394), Online publication date: 1-Dec-2011. Kayrak M, Bacaksiz A, Ulgen M, Vatankulu M, Zengin K, Ayhan S, Basaralı M, Büyükbas S and Kiyici A (2010) Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study, Heart and Vessels, 10.1007/s00380-010-0036-x, 26:2, (131-137), Online publication date: 1-Mar-2011. Lattanzio S, Santilli F, Vitale G, Caruso R, Davì V, Di Rosa S, Vazzana N, Ciabattoni G, Mansueto S and Davì G (2010) Soluble CD40L in Mediterranean Spotted Fever: Relation to oxidative stress and platelet activation, Thrombosis Research, 10.1016/j.thromres.2009.06.010, 125:4, (362-364), Online publication date: 1-Apr-2010. Lukanov T, Bojinova S, Popova V, Emin A, Veleva G, Gecheva S and Konova E (2009) Flow Cytometric Investigation of CD40-CD40 Ligand System in Preeclampsia and Normal Pregnancy, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029608331229, 16:3, (306-312), Online publication date: 1-Jun-2010. Oberheiden T, Blahak C, Nguyen X, Fatar M, Elmas E, Morper N, Dempfle C, Bäzner H, Hennerici M, Borggrefe M and Kälsch T (2010) Activation of platelets and cellular coagulation in cerebral small-vessel disease, Blood Coagulation & Fibrinolysis, 10.1097/MBC.0b013e328340147c, 21:8, (729-735), Online publication date: 1-Dec-2010. Huang G, Shih C, Wu C, Hu M, Tsai C, Liaw W, Chan S and Li C (2010) Hypertonic Saline, Mannitol and Hydroxyethyl Starch Preconditioning of Platelets Obtained From Septic Patients Attenuates CD40 Ligand Expression In Vitro, Journal of Trauma: Injury, Infection & Critical Care, 10.1097/TA.0b013e3181a6028e, 68:2, (331-336), Online publication date: 1-Feb-2010. Koenig G and Gurm H (2010) Resistance to Antiplatelet Drugs Antithrombotic Drug Therapy in Cardiovascular Disease, 10.1007/978-1-60327-235-3_24, (449-464), . Papapanagiotou D, Nicu E, Bizzarro S, Gerdes V, Meijers J, Nieuwland R, van der Velden U and Loos B (2009) Periodontitis is associated with platelet activation, Atherosclerosis, 10.1016/j.atherosclerosis.2008.05.035, 202:2, (605-611), Online publication date: 1-Feb-2009. Law C and Grewal I (2009) Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges Therapeutic Targets of the TNF Superfamily, 10.1007/978-0-387-89520-8_2, (8-36), . Peters A, Stunz L and Bishop G (2009) CD40 and autoimmunity: The dark side of a great activator, Seminars in Immunology, 10.1016/j.smim.2009.05.012, 21:5, (293-300), Online publication date: 1-Oct-2009. Garraud O and Cognasse F (2009) Immunologie plaquettaire et réponse immune, Transfusion Clinique et Biologique, 10.1016/j.tracli.2009.03.002, 16:2, (106-117), Online publication date: 1-May-2009. Lukanov T, Bojinova S, Emin A, Veleva G, Popova V and Konova E (2009) Upregulation of the CD40-CD40 ligand system in pre-eclampsia, International Journal of Gynecology & Obstetrics, 10.1016/j.ijgo.2009.01.034, 105:3, (257-260), Online publication date: 1-Jun-2009. Richard S, Toussaint-Hacquard M and Lecompte T (2009) Variabilité de réponse plaquettaire à l'aspirine et nouvelles cibles thérapeutiques, Journal des Maladies Vasculaires, 10.1016/j.jmv.2008.10.009, 34:1, (16-25), Online publication date: 1-Feb-2009. Blair P and Freedman J (2008) Aspirin resistance in atherosclerosis, Current Atherosclerosis Reports, 10.1007/s11883-008-0022-2, 10:2, (149-157), Online publication date: 1-Apr-2008. Kälsch T, Elmas E, Nguyen X, Leweling H, Klüter H, Borggrefe M and Dempfle C (2008) Alimentary lipemia enhances procoagulatory effects of inflammation in patients with a history of acute myocardial infarction complicated by ventricular fibrillation, International Journal of Cardiology, 10.1016/j.ijcard.2006.11.249, 123:2, (131-137), Online publication date: 1-Jan-2008. Dyken M and Im K (2008) Sleep-Disordered Breathing and Stroke, Sleep Medicine Clinics, 10.1016/j.jsmc.2008.04.013, 3:3, (361-376), Online publication date: 1-Sep-2008. Crist S, Sprague D and Ratliff T (2008) Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes, Blood, 10.1182/blood-2007-05-088161, 111:7, (3553-3561), Online publication date: 1-Apr-2008. Chello M, Spadaccio C, Patti G, Lusini M, Barbato R, Goffredo C, Di Sciascio G and Covino E (2008) Simvastatin reduces platelet–endocardium adhesion in atrial fibrillation, Atherosclerosis, 10.1016/j.atherosclerosis.2007.08.021, 197:2, (588-595), Online publication date: 1-Apr-2008. Tan S, Tambar S, Chohan S, Ramsey-Goldman R and Lee C (2008) Acute Myocardial Infarction After Treatment of Thrombocytopenia in a Young Woman With Systemic Lupus Erythematosus, JCR: Journal of Clinical Rheumatology, 10.1097/RHU.0b013e31817de0fb, 14:6, (350-352), Online publication date: 1-Dec-2008. Rizvi M, Pathak D, Freedman J and Chakrabarti S (2008) CD40–CD40 ligand interactions in oxidative stress, inflammation and vascular disease, Trends in Molecular Medicine, 10.1016/j.molmed.2008.09.006, 14:12, (530-538), Online publication date: 1-Dec-2008. Ferroni P, Guagnano M, Falco A, Paoletti V, Manigrasso M, Michetti N, Santilli F, Guadagni F, Basili S and Davì G (2008) Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria, Clinical Science, 10.1042/CS20070307, 114:6, (449-455), Online publication date: 1-Mar-2008. Morel O, Morel N, Freyssinet J and Toti F (2009) Platelet microparticles and vascular cells interactions: A checkpoint between the haemostatic and thrombotic responses, Platelets, 10.1080/09537100701817232, 19:1, (9-23), Online publication date: 1-Jan-2008. Cognasse F, Osselaer J and Garraud O (2007) Les cytokines des plaquettes et leurs effets lors des transfusions de concentrés de plaquettes, Transfusion Clinique et Biologique, 10.1016/j.tracli.2007.04.009, 14:1, (69-78), Online publication date: 1-May-2007. Cognasse F, Lafarge S, Chavarin P, Acquart S and Garraud O (2006) Lipopolysaccharide induces sCD40L release through human platelets TLR4, but not TLR2 and TLR9, Intensive Care Medicine, 10.1007/s00134-006-0488-8, 33:2, (382-384), Online publication date: 5-Feb-2007. PIGNATELLI P, SANGUIGNI V, LENTI L, LOFFREDO L, CARNEVALE R, SORGE R and VIOLI F (2007) Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2007.02533.x, 5:6, (1170-1178), Online publication date: 1-Jun-2007. Kälsch T, Elmas E, Nguyen X, Kralev S, Leweling H, Klüter H, Dempfle C and Borggrefe M (2007) Effects of alimentary lipemia and inflammation on platelet CD40-ligand, Thrombosis Research, 10.1016/j.thromres.2006.12.022, 120:5, (703-708), Online publication date: 1-Jan-2007. Young R, Naseem K, Pasupathy S, Ahilathirunayagam S, Chaparala R and Homer-Vanniasinkam S (2007) Platelet membrane CD154 and sCD154 i
Referência(s)